Editas Medicine, Inc. (NASDAQ:EDIT) received a $27.00 price objective from stock analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Wednesday. The brokerage presently has a “hold” rating on the stock. J P Morgan Chase & Co’s price objective would suggest a potential upside of 50.17% from the stock’s current price.

A number of other brokerages also recently commented on EDIT. Cann reissued a “hold” rating on shares of Editas Medicine in a research note on Thursday. SunTrust Banks, Inc. assumed coverage on shares of Editas Medicine in a research note on Thursday, July 13th. They issued a “hold” rating and a $17.00 target price on the stock. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Wednesday, July 12th. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.03.

Editas Medicine (EDIT) opened at 17.98 on Wednesday. The firm’s market cap is $732.31 million. The firm has a 50 day moving average of $16.99 and a 200 day moving average of $18.99. Editas Medicine has a 1-year low of $12.43 and a 1-year high of $29.20.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 9th. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.08. Editas Medicine had a negative net margin of 1,864.00% and a negative return on equity of 63.29%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $2.20 million. During the same period in the prior year, the business posted ($0.54) EPS. The business’s revenue was down 8.8% on a year-over-year basis. On average, equities research analysts expect that Editas Medicine will post ($3.05) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “J P Morgan Chase & Co Analysts Give Editas Medicine, Inc. (EDIT) a $27.00 Price Target” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/10/j-p-morgan-chase-co-analysts-give-editas-medicine-inc-edit-a-27-00-price-target.html.

In other news, insider Gerald Frank Cox purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were purchased at an average price of $14.15 per share, with a total value of $56,600.00. Following the purchase, the insider now directly owns 4,000 shares of the company’s stock, valued at approximately $56,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Bitterman sold 1,000,000 shares of Editas Medicine stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $17.00, for a total transaction of $17,000,000.00. The disclosure for this sale can be found here.

A number of large investors have recently added to or reduced their stakes in EDIT. Pacad Investment Ltd. purchased a new stake in Editas Medicine during the second quarter valued at about $287,000. Airain ltd purchased a new stake in Editas Medicine during the second quarter valued at about $255,000. Legal & General Group Plc increased its stake in Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock valued at $145,000 after buying an additional 6,535 shares during the period. Bank of New York Mellon Corp increased its stake in Editas Medicine by 123.8% in the second quarter. Bank of New York Mellon Corp now owns 142,122 shares of the company’s stock valued at $2,385,000 after buying an additional 78,632 shares during the period. Finally, State of Wisconsin Investment Board purchased a new stake in Editas Medicine during the second quarter valued at about $419,000. 67.87% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.